Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1954 2
1968 1
1972 3
1973 4
1974 7
1975 2
1976 4
1978 2
1979 3
1980 4
1981 2
1982 1
1983 6
1984 3
1985 6
1986 4
1987 7
1988 4
1989 4
1990 6
1991 7
1992 2
1993 5
1994 8
1995 5
1996 13
1997 8
1998 5
1999 10
2000 10
2001 12
2002 5
2003 5
2004 5
2005 4
2006 7
2007 10
2008 8
2009 8
2010 4
2011 12
2012 11
2013 9
2014 8
2015 10
2016 13
2017 12
2018 18
2019 11
2020 9
2021 22
2022 22
2023 16
2024 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

383 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T; KEYNOTE-426 Investigators. Rini BI, et al. Among authors: markus m. N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16. N Engl J Med. 2019. PMID: 30779529 Clinical Trial.
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators. Powles T, et al. Lancet Oncol. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051178 Clinical Trial.
Plasmodium vivax.
Flannery EL, Markus MB, Vaughan AM. Flannery EL, et al. Among authors: markus mb. Trends Parasitol. 2019 Jul;35(7):583-584. doi: 10.1016/j.pt.2019.04.005. Epub 2019 Jun 5. Trends Parasitol. 2019. PMID: 31176582 Review. No abstract available.
Lipoprotein(a) and Metabolic Syndrome.
Buchmann N, Ittermann T, Demuth I, Markus MRP, Völzke H, Dörr M, Friedrich N, Lerch MM, Santos RD, Schipf S, Steinhagen-Thiessen E. Buchmann N, et al. Among authors: markus mrp. Dtsch Arztebl Int. 2022 Apr 15;119(15):270-276. doi: 10.3238/arztebl.m2022.0153. Dtsch Arztebl Int. 2022. PMID: 35331368 Free PMC article.
Plasmodium: Yet More Don'ts.
Markus MB. Markus MB. Trends Parasitol. 2019 Feb;35(2):101-102. doi: 10.1016/j.pt.2018.11.006. Epub 2018 Dec 15. Trends Parasitol. 2019. PMID: 30563780 No abstract available.
The malarial hypnozoite.
Markus MB. Markus MB. Lancet. 1980 Apr 26;1(8174):936. doi: 10.1016/s0140-6736(80)90871-5. Lancet. 1980. PMID: 6103294 No abstract available.
RBM4: a multifunctional RNA-binding protein.
Markus MA, Morris BJ. Markus MA, et al. Int J Biochem Cell Biol. 2009 Apr;41(4):740-3. doi: 10.1016/j.biocel.2008.05.027. Epub 2008 Aug 3. Int J Biochem Cell Biol. 2009. PMID: 18723113 Review.
383 results